Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA

Circulation Research

Volumn 85, Issue 7, 1999, Pages 614-622

  Wang, Hongwei ^a   Katovich, Michael J ^a   Gelband, Craig H ^a   Reaves, Phyllis Y ^a   Phillips, M Ian ^a   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Endothelial cell; Gene therapy; Hypertension; Virally mediated delivery

Indexed keywords

COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; ENZYME INHIBITION; GENE TARGETING; GENE THERAPY; HEART LEFT VENTRICLE FUNCTION; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0033214337     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.7.614     Document Type: Article

References (37)

1. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev. 1992;13: 329-380.
2. Timmermans PBMWM, Wang PC, Chiu AT, Herblin MF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993.
3. Inagami T. The renin-angiotensin system. Essays Biochem. 1994;28: 147-164.
4. Parmley WW. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. Am J Med. 1998;105: 27S-31S.
5. Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 1998;105(1A):40S-47S.
6. Roman MJ, Alderman MH, Pickening TG, Pini R, Keating J, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens. 1998;11:387-396.
7. Hricik DE, Browning PJ, Kopelman R, Goorno WE, Madias NE, Dzau VJ. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983;308:373-376.
8. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
9. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. 1997;15:1579-1592.
10. Soubrier F. Blood pressure gene at the angiotensin I-converting enzyme locus: chronicle of gene foretold. Circulation. 1998;97:1763-1765.
11. Yang H, Lu D, Raizada MK. Lack of cross talk between alpha 1-adrenergic and angiotensin type 1 receptors in neurons of spontaneously hypertensive rat brain. Hypertension. 1996;27:1277-1283.
12. Sumners C, Raizada MK, Rang J, Lu D. Posner P. Receptor-mediated effects of angiotensin II on neurons. Front Neuroendocrinol. 1994; 15: 203-230.
13. Raizada MK, Lu D, Tang W, Kurian P, Sumners C. Increased angiotensin II type-1 receptor gene expression in neuronal cultures from spontaneously hypertensive rats. Endocrinology. 1993;132:1715-1722.
14. 1-Rs and angiotensin II action in astroglial and neuronal cells in primary cultures from the brain. Proc Natl Acad Sci USA. 1995;92:1162-1166.
15. Sanger F, Coulson AR, Hong GF, Hill DF, Petersen GB. Nucleotide sequence of bacteriophage lambda DNA. J MoL Biol. 1982:162:729-773.
16. Sambrook T, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989:6.22-6.23, 16.30-16.47.
17. Lu D, Raizada MK. Delivery of angiotensin II type 1 receptor antisense inhibits angiotensin action in neurons. Proc Natl Acad Sci U S A. 1995; 92:2914-2918.
18. Lu D, Yu K, Paddy MR, Rowland NE, Raizada MK. Regulation of norepinephrine transport system by angiotensin II in neuronal cultures of normotensive and spontaneously hypertensive rat brains. Endocrinology. 1996;137:763-772.
19. 1 receptor antisense in neurons and SMC. Am J Physiol. 1998;274:H719-H727.
20. Wang AM Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:9717-9721.
21. Neels HIM, Van Sande ME, Scharpe SL. Sensitive colorimetric assay for angiotensin converting enzyme in serum. Clin Chem. 1983;29: 1399-1403.
22. Martens JR, Gelband CH. Alterations in rat interlobar artery membrane potential and K channels in hypertension. Circ Res. 1996;79:259-301.
23. Iyer SN, Lu D, Katovich MJ, Raizada MK. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense. Proc Natl Acad Sci U S A. 1996;93:9960-9965.
24. Lu D, Raizada MK, Iyer S, Reaves P, Yang H, Katovich MJ. Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension. 1997;30:363-370.
25. Martens JR, Reaves PY; Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada, MK, Gelband CH. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proc Natl Acad Sci U S A. 1998;95: 2664-2669.
26. Wu JN, Edwards D, Berecek KH. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin converting enzyme inhibitor captopril. Hypertension. 1994; 23:819-822.
27. Regitz-Zagrosek V, Auch-Scheweek W, Neuss M, Peck E. Regulation of the angiotensin receptor subtypes in cell culture, animal models and human diseases. Eur Heart J. 1994;15:92-97.
28. Hunyady L, Tian Y, Sandberg K, Balla T, Catt KJ. Divergent conformational requirements for angiotensin II receptor internalization and signaling. Kidney Int. 1994;46:1496-1498.
29. Gelband CH, Sumners C, Lu D, Raizada MK. Angiotensin receptors and norepinephrine neuromodulation: implications of functional coupling. Regul Pept. 1997;72:139-145.
30. Martens JR, Gelband CH. Ion channels in vascular smooth muscle: alterations in essential hypertension. Proc Soc Exp Biol Med. 1998:218: 192-203.
31. 1R) antisense in vitro and in vivo. In: Abelson JN, Simon MI, eds. Methods in Enzymology: Antisense Technology. Vol 314. Orlando, Fla: Academic Press; 1999:581-590.
32. Folkman J Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA. 1979;76:5217-5221.
33. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacot Physiol Suppl. 1996;3: S125-S131.
34. de Gasparo M, Levens N. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme? Pharmacol Toxicol. 1998;82:257-271.
35. Tang SS, Rogg H, Schumacher R, Dzau VJ. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology. 1992;131:374-380.
36. 1) receptor in brain neurons. Endocrinology. 1998;139:365-375.
37. Brown NJ, Vaughn DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.